Acticor Biotech: Results of the Phase 2 GARDEN Study in COVID-19-Related Acute Respiratory Distress Syndrome

Regulatory News: Acticor Biotech (Paris:ALACT), a clinical stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announced today the results of

Related Keywords

Mediolanum ,Lombardia ,Italy ,France ,Brazil ,French ,Newton Biocapital ,Yannick Pletan ,Thromb Haemost ,Head Of The Department Anaesthesiology ,Venture Investment ,French National Institute Of Health ,Strasbourg University Hospitals ,Regulatory News ,Global Coordinator ,Hautepierre Hospital ,Strasbourg University ,Chief Medical Officer ,General Manager ,Acticor Biotech ,Chief Executive Officer ,Chief Scientific ,French National Institute ,Medical Research ,Mirae Asset Capital ,Primer Capital ,Euronext Growth Paris ,Acticor ,Biotech ,Results ,Hase ,Garden ,Study ,Covid ,Elated ,Cute ,Espiratory ,Distress ,Yndrome ,